146 related articles for article (PubMed ID: 37977350)
21. Targeting the ∆133p53 isoform can restore chemosensitivity in 5-fluorouracil-resistant cholangiocarcinoma cells.
Nutthasirikul N; Hahnvajanawong C; Techasen A; Limpaiboon T; Leelayuwat C; Chau-In S; Jearanaikoon P
Int J Oncol; 2015 Dec; 47(6):2153-64. PubMed ID: 26459801
[TBL] [Abstract][Full Text] [Related]
22. Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma.
Chen MH; Chiang KC; Cheng CT; Huang SC; Chen YY; Chen TW; Yeh TS; Jan YY; Wang HM; Weng JJ; Chang PM; Liu CY; Li CP; Chao Y; Chen MH; Huang CY; Yeh CN
Oncotarget; 2014 May; 5(9):2372-89. PubMed ID: 24796583
[TBL] [Abstract][Full Text] [Related]
23. Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma.
Du J; Lv X; Zhang Z; Huang Z; Zhang E
Front Immunol; 2023; 14():1142690. PubMed ID: 36936931
[TBL] [Abstract][Full Text] [Related]
24. KIF14 promotes proliferation, lymphatic metastasis and chemoresistance through G3BP1/YBX1 mediated NF-κB pathway in cholangiocarcinoma.
Jiang W; Wang J; Yang X; Shan J; Zhang Y; Shi X; Wang Y; Chenyan A; Chang J; Wang Y; Yu Y; Li C; Li X
Oncogene; 2023 Apr; 42(17):1392-1404. PubMed ID: 36922675
[TBL] [Abstract][Full Text] [Related]
25. Wnt-TCF7-SOX9 axis promotes cholangiocarcinoma proliferation and pemigatinib resistance in a FGF7-FGFR2 autocrine pathway.
Liu Z; Liu J; Chen T; Wang Y; Shi A; Li K; Li X; Qiu B; Zheng L; Zhao L; Shu L; Lian S; Huang S; Zhang Z; Xu Y
Oncogene; 2022 May; 41(20):2885-2896. PubMed ID: 35428876
[TBL] [Abstract][Full Text] [Related]
26. Amplified in breast cancer 1 enhances human cholangiocarcinoma growth and chemoresistance by simultaneous activation of Akt and Nrf2 pathways.
Chen Q; Li W; Wan Y; Xia X; Wu Q; Chen Y; Lai Z; Yu C; Li W
Hepatology; 2012 Jun; 55(6):1820-9. PubMed ID: 22213475
[TBL] [Abstract][Full Text] [Related]
27. Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance.
Fouassier L; Marzioni M; Afonso MB; Dooley S; Gaston K; Giannelli G; Rodrigues CMP; Lozano E; Mancarella S; Segatto O; Vaquero J; Marin JJG; Coulouarn C
Liver Int; 2019 May; 39 Suppl 1():43-62. PubMed ID: 30903728
[TBL] [Abstract][Full Text] [Related]
28. Orotate phosphoribosyl transferase mRNA expression and the response of cholangiocarcinoma to 5-fluorouracil.
Hahnvajanawong C; Chaiyagool J; Seubwai W; Bhudhisawasdi V; Namwat N; Khuntikeo N; Sripa B; Pugkhem A; Tassaneeyakul W
World J Gastroenterol; 2012 Aug; 18(30):3955-61. PubMed ID: 22912546
[TBL] [Abstract][Full Text] [Related]
29. DNA adducts, detected by 32P postlabelling, in human cholangiocarcinoma.
Khan SA; Carmichael PL; Taylor-Robinson SD; Habib N; Thomas HC
Gut; 2003 Apr; 52(4):586-91. PubMed ID: 12631674
[TBL] [Abstract][Full Text] [Related]
30. Upregulation of retinoic acid receptor-β reverses drug resistance in cholangiocarcinoma cells by enhancing susceptibility to apoptosis.
Ren HY; Chen B; Huang GL; Liu Y; Shen DY
Mol Med Rep; 2016 Oct; 14(4):3602-8. PubMed ID: 27599527
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA-144 suppresses cholangiocarcinoma cell proliferation and invasion through targeting platelet activating factor acetylhydrolase isoform 1b.
Yang R; Chen Y; Tang C; Li H; Wang B; Yan Q; Hu J; Zou S
BMC Cancer; 2014 Dec; 14():917. PubMed ID: 25479763
[TBL] [Abstract][Full Text] [Related]
32. Hypoxia-induced SKA3 promoted cholangiocarcinoma progression and chemoresistance by enhancing fatty acid synthesis via the regulation of PAR-dependent HIF-1a deubiquitylation.
Chen Y; Xu X; Wang Y; Zhang Y; Zhou T; Jiang W; Wang Z; Chang J; Liu S; Chen R; Shan J; Wang J; Wang Y; Li C; Li X
J Exp Clin Cancer Res; 2023 Oct; 42(1):265. PubMed ID: 37821935
[TBL] [Abstract][Full Text] [Related]
33. Dual blockade of the Hedgehog and ERK1/2 pathways coordinately decreases proliferation and survival of cholangiocarcinoma cells.
Jinawath A; Akiyama Y; Sripa B; Yuasa Y
J Cancer Res Clin Oncol; 2007 Apr; 133(4):271-8. PubMed ID: 17294242
[TBL] [Abstract][Full Text] [Related]
34. Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study.
Golan T; Raitses-Gurevich M; Kelley RK; Bocobo AG; Borgida A; Shroff RT; Holter S; Gallinger S; Ahn DH; Aderka D; Apurva J; Bekaii-Saab T; Friedman E; Javle M
Oncologist; 2017 Jul; 22(7):804-810. PubMed ID: 28487467
[TBL] [Abstract][Full Text] [Related]
35. Tumor Cell-Derived Extracellular Vesicles Promote the Growth, Metastasis and Chemoresistance in Cholangiocarcinoma by Delivering microRNA-210 to Downregulate RECK.
Fu Y; Liu Y; Liu K; Tan L
Mol Biotechnol; 2023 Jul; 65(7):1151-1164. PubMed ID: 36454533
[TBL] [Abstract][Full Text] [Related]
36. Blockade of chloride channel-3 enhances cisplatin sensitivity of cholangiocarcinoma cells though inhibiting autophagy.
Han Y; Zhou Y; Zhou L; Jia X; Yu X; An X; Shi Z
Can J Physiol Pharmacol; 2022 Jul; 100(7):584-593. PubMed ID: 35413227
[TBL] [Abstract][Full Text] [Related]
37. Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines.
Tepsiri N; Chaturat L; Sripa B; Namwat W; Wongkham S; Bhudhisawasdi V; Tassaneeyakul W
World J Gastroenterol; 2005 May; 11(18):2748-53. PubMed ID: 15884115
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of membrane metalloendopeptidase inhibits substance P stimulation of cholangiocarcinoma growth.
Meng F; DeMorrow S; Venter J; Frampton G; Han Y; Francis H; Standeford H; Avila S; McDaniel K; McMillin M; Afroze S; Guerrier M; Quezada M; Ray D; Kennedy L; Hargrove L; Glaser S; Alpini G
Am J Physiol Gastrointest Liver Physiol; 2014 May; 306(9):G759-68. PubMed ID: 24603459
[TBL] [Abstract][Full Text] [Related]
39. Suppression of galectin-3 expression enhances apoptosis and chemosensitivity in liver fluke-associated cholangiocarcinoma.
Wongkham S; Junking M; Wongkham C; Sripa B; Chur-In S; Araki N
Cancer Sci; 2009 Nov; 100(11):2077-84. PubMed ID: 19723119
[TBL] [Abstract][Full Text] [Related]
40. Molecular pathogenesis of cholangiocarcinoma.
Rizvi S; Gores GJ
Dig Dis; 2014; 32(5):564-9. PubMed ID: 25034289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
